Insights
Search Results
Client Highlights
11.09.22
Firm Advises ScienTech Medical on US$83.4 Million IPO
On November 8, 2022, LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (ScienTech Medical) successfully listed on the Main Board of the Stock Exchange of Hong Kong, raising approximately HK$654.6 million (US$83.4 million) from a global offering of 22,455,000 H shares, or approximately HK$752.7 million (US$95.9 million) if the underwriters fully exercise their over-allotment option to purchase 3,368,000 additional H shares. Wilson Sonsini Goodrich & Rosati acted as U.S. and Hong Kong counsel to ScienTech Medical in the global offering and listing.
Client Highlights
7.21.21
Wilson Sonsini Advises PacBio on Omniome Acquisition, Private Placement and Intended Collaboration Expansion with Invitae
On July 20, 2021, Pacific Biosciences of California (PacBio), a leading provider of high-quality, long-read sequencing platforms, announced that it has signed a definitive merger agreement to acquire Omniome, a San Diego-based company developing a highly differentiated, proprietary short-read sequencing platform capable of delivering high accuracy. Upon closing of the acquisition, PacBio will be uniquely positioned as the only company with both highly accurate long-read and short-read sequencing platforms. The company also announced two other transactions: a private placement for aggregate proceeds of approximately $300 million in connection with the proposed acquisition, and an intent to expand a multi-year collaboration with Invitae Corporation to develop a production-scale high-throughput HiFi sequencing platform to include the sequencing technology developed by Omniome.
Client Highlights
6.22.21
Wilson Sonsini Advises InSilico Medicine on $255 Million Series C Financing
On June 22, 2021, Hong Kong-based InSilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million Series C financing led by Warburg Pincus. The financing included participation by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, and Baidu Ventures and new investors including CPE, Hillhouse Capital, OrbiMed, Mirae Asset, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China, and Sage Partners.